115 related articles for article (PubMed ID: 2939038)
1. Regional fibrosis after intraperitoneal administration of mafosfamide.
Roberts JD; Newman RA; Kimberly PJ; Hacker MP
Invest New Drugs; 1986; 4(1):61-5. PubMed ID: 2939038
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
[TBL] [Abstract][Full Text] [Related]
3. Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor.
Wagner T; Mittendorff F; Walter E
Cancer Res; 1986 May; 46(5):2214-9. PubMed ID: 3697966
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.
Slavc I; Schuller E; Czech T; Hainfellner JA; Seidl R; Dieckmann K
J Neurooncol; 1998; 38(2-3):213-8. PubMed ID: 9696374
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling.
Goldstein M; Roos WP; Kaina B
Toxicol Appl Pharmacol; 2008 May; 229(1):20-32. PubMed ID: 18289623
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
[TBL] [Abstract][Full Text] [Related]
9. Micronucleus test with cyclophosphamide administered by intraperitoneal injection and oral gavage.
Wakata A; Yamashita T; Tamaoki M; Ohshima T; Kojima M
Mutat Res; 1989 Aug; 223(4):369-72. PubMed ID: 2747720
[TBL] [Abstract][Full Text] [Related]
10. The effects of low-dose erythropoiesis-stimulating agents on peritoneal fibrosis induced by chemical peritonitis and on peritoneal tissue MMP-2 and TIMP-2 Levels in rats.
Yildirim A; Ozkan OV; Aslan A; Koseoglu Z; Borazan A
Ren Fail; 2009; 31(7):567-72. PubMed ID: 19839852
[TBL] [Abstract][Full Text] [Related]
11. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.
Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J
J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Listeria monocytogenes infection of the peritoneum in mice with cyclosporine a-induced peritonitis.
Prats N; López S; Domingo M; Briones V; Domínguez L; Marco AJ
J Comp Pathol; 2002; 127(2-3):178-85. PubMed ID: 12354529
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
16. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide.
Davidoff AN; Mendelow BV
Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal Infusion of Neutral-pH Superoxidized Solution in Rats: Evaluation of Toxicity and Complications on Peritoneal Surface and Liver.
Aras A; Karaman E; Yıldırım S; Yılmaz Ö; Kızıltan R; Karaman K
Med Sci Monit; 2017 Feb; 23():960-965. PubMed ID: 28224975
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.
Kohn FR; Sladek NE
Immunopharmacol Immunotoxicol; 1988; 10(3):387-98. PubMed ID: 3058776
[TBL] [Abstract][Full Text] [Related]
19. Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.
Wagner T; Zink M; Schwieder G
J Cancer Res Clin Oncol; 1987; 113(2):160-5. PubMed ID: 3104347
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal toxicity of Hytrast: an experimental study.
Ginai AZ; Ten Kate FJ; Ten Berg RG; Hoornstra K
Br J Radiol; 1986 Nov; 59(707):1079-82. PubMed ID: 3790893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]